{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:57:22Z","timestamp":1780055842634,"version":"3.54.0"},"posted":{"date-parts":[[2024,4,19]]},"group-title":"Hematology","reference-count":51,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,4,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Early therapeutic intervention in high-risk SMM (HR-SMM) has demonstrated benefit in previous studies of lenalidomide with or without dexamethasone. Triplets and quadruplet studies have been examined in this same population. However, to date, none of these studies examined the impact of depth of response on long-term outcomes of participants treated with lenalidomide-based therapy, and whether the use of the 20\/2\/20 model or the addition of genomic alterations can further define the population that would benefit the most from early therapeutic intervention. Here, we present the results of the phase II study of the combination of ixazomib, lenalidomide, and dexamethasone in patients with HR-SMM with long-term follow-up and baseline single-cell tumor and immune sequencing that help refine the population to be treated for early intervention studies.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is a phase II trial of ixazomib, lenalidomide, and dexamethasone (IRD) in HR-SMM. Patients received 9 cycles of induction therapy with ixazomib 4mg on days 1, 8, and 15; lenalidomide 25mg on days 1-21; and dexamethasone 40mg on days 1, 8, 15, and 22. The induction phase was followed by maintenance with ixazomib 4mg on days 1, 8, and 15; and lenalidomide 15mg d1-21 for 15 cycles for 24 months of treatment. The primary endpoint was progression-free survival after 2 years of therapy. Secondary endpoints included depth of response, biochemical progression, and correlative studies included single-cell RNA sequencing and\/or whole-genome sequencing of the tumor and single-cell sequencing of immune cells at baseline.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fifty-five patients, with a median age of 64, were enrolled in the study. The overall response rate was 93%, with 31% of patients achieving a complete response and 45% achieving a very good partial response or better. The most common grade 3 or greater treatment-related hematologic toxicities were neutropenia (16 patients; 29%), leukopenia (10 patients; 18%), lymphocytopenia (8 patients; 15%), and thrombocytopenia (4 patients; 7%). Non-hematologic grade 3 or greater toxicities included hypophosphatemia (7 patients; 13%), rash (5 patients; 9%), and hypokalemia (4 patients; 7%). After a median follow-up of 50 months, the median progression-free survival (PFS) was 48.6 months (95% CI: 39.9 \u2013 not reached; NR) and median overall survival has not been reached. Patients achieving VGPR or better had a significantly better progression-free survival (p&lt;0.001) compared to those who did not achieve VGPR (median PFS 58.2 months vs. 31.3 months). Biochemical progression preceded or was concurrent with the development of SLiM-CRAB criteria in eight patients during follow-up, indicating that biochemical progression is a meaningful endpoint that correlates with the development of end-organ damage. High-risk 20\/2\/20 participants had the worst PFS compared to low- and intermediate-risk participants. The use of whole genome or single-cell sequencing of tumor cells identified high-risk aberrations that were not identified by FISH alone and aided in the identification of participants at risk of progression. scRNA-seq analysis revealed a positive correlation between MHC class I expression and response to proteasome inhibition and at the same time a decreased proportion of GZMB+ T cells within the clonally expanded CD8+ T cell population correlated with suboptimal response.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>\n                    Ixazomib, lenalidomide and dexamethasone in HR-SMM demonstrates significant clinical activity with an overall favorable safety profile. Achievement of VGPR or greater led to significant improvement in time to progression, suggesting that achieving deep response is beneficial in HR-SMM. Biochemical progression correlates with end-organ damage. Patients with high-risk FISH and lack of deep response had poor outcomes.\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                    identifier: (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02916771\">NCT02916771<\/jats:ext-link>\n                    )\n                  <\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2024.04.19.24306082","type":"posted-content","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T20:05:17Z","timestamp":1713557117000},"source":"Crossref","is-referenced-by-count":5,"title":["Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone"],"prefix":"10.64898","author":[{"given":"Omar","family":"Nadeem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle P.","family":"Aranha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Redd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Timonian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Magidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth D.","family":"Lightbody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Alberge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bertamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit K.","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"El-Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bustoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Laubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Getz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Trippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romanos","family":"Sklavenitis-Pistofidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2024042307500992000_2024.04.19.24306082v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070389"},{"key":"2024042307500992000_2024.04.19.24306082v1.2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-108357"},{"key":"2024042307500992000_2024.04.19.24306082v1.3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-088443"},{"key":"2024042307500992000_2024.04.19.24306082v1.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-568899"},{"key":"2024042307500992000_2024.04.19.24306082v1.5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","year":"2018","journal-title":"Blood Cancer J"},{"key":"2024042307500992000_2024.04.19.24306082v1.6","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","article-title":"Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study","volume":"10","year":"2023","journal-title":"The Lancet Haematology"},{"key":"2024042307500992000_2024.04.19.24306082v1.7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/jamaoncol.2020.5585","article-title":"Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models","volume":"7","year":"2021","journal-title":"JAMA Oncology"},{"key":"2024042307500992000_2024.04.19.24306082v1.8","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression","volume":"38","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024042307500992000_2024.04.19.24306082v1.9","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","year":"2018","journal-title":"Nat Commun"},{"key":"2024042307500992000_2024.04.19.24306082v1.10","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","article-title":"MYC dysregulation in the progression of multiple myeloma","volume":"34","year":"2020","journal-title":"Leukemia"},{"key":"2024042307500992000_2024.04.19.24306082v1.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22140-0"},{"key":"2024042307500992000_2024.04.19.24306082v1.12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41467-020-20524-2","article-title":"The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma","volume":"12","year":"2021","journal-title":"Nat Commun"},{"key":"2024042307500992000_2024.04.19.24306082v1.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300439"},{"key":"2024042307500992000_2024.04.19.24306082v1.14","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma","volume":"38","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024042307500992000_2024.04.19.24306082v1.15","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood.2020009752","article-title":"Persistent challenges with treating multiple myeloma early","volume":"137","year":"2021","journal-title":"Blood"},{"key":"2024042307500992000_2024.04.19.24306082v1.16","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H , Bahlis NJ : Smoldering Multiple Myeloma : Taking the narrow over the wide path? Blood, 2024","DOI":"10.1182\/blood.2024023880"},{"key":"2024042307500992000_2024.04.19.24306082v1.17","doi-asserted-by":"crossref","unstructured":"Ghobrial IM , Gormley N , Kumar SK , et al: Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma. Blood Cancer Discovery:OF1\u2013OF7, 2024","DOI":"10.1158\/2643-3230.BCD-24-0022"},{"key":"2024042307500992000_2024.04.19.24306082v1.18","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood-2019-125204","article-title":"Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd","volume":"134","year":"2019","journal-title":"Blood"},{"key":"2024042307500992000_2024.04.19.24306082v1.19","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/jamaoncol.2021.3971","article-title":"Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial","volume":"7","year":"2021","journal-title":"JAMA Oncol"},{"key":"2024042307500992000_2024.04.19.24306082v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.10.017"},{"key":"2024042307500992000_2024.04.19.24306082v1.21","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood-2022-168930","article-title":"Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial","volume":"140","year":"2022","journal-title":"Blood"},{"key":"2024042307500992000_2024.04.19.24306082v1.22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41587-022-01468-y","article-title":"Haplotype-aware analysis of somatic copy number variations from single-cell transcriptomes","volume":"41","year":"2023","journal-title":"Nat Biotechnol"},{"key":"2024042307500992000_2024.04.19.24306082v1.23","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"2024042307500992000_2024.04.19.24306082v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"2024042307500992000_2024.04.19.24306082v1.25","first-page":"e418","article-title":"Updated Diagnostic Criteria and Staging System for Multiple Myeloma","volume":"35","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2024042307500992000_2024.04.19.24306082v1.26","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/JCO.2019.37.15_suppl.8001","article-title":"E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma","volume":"37","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"2024042307500992000_2024.04.19.24306082v1.27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002827"},{"key":"2024042307500992000_2024.04.19.24306082v1.28","doi-asserted-by":"crossref","first-page":"e0267979","DOI":"10.1371\/journal.pone.0267979","article-title":"Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma","volume":"17","year":"2022","journal-title":"PLoS One"},{"key":"2024042307500992000_2024.04.19.24306082v1.29","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0047"},{"key":"2024042307500992000_2024.04.19.24306082v1.30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4616"},{"key":"2024042307500992000_2024.04.19.24306082v1.31","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41423-023-00997-z","article-title":"Themis suppresses the effector function of CD8+ T cells in acute viral infection","volume":"20","year":"2023","journal-title":"Cellular & Molecular Immunology"},{"key":"2024042307500992000_2024.04.19.24306082v1.32","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood.2020008787","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"137","year":"2021","journal-title":"Blood"},{"key":"2024042307500992000_2024.04.19.24306082v1.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"2024042307500992000_2024.04.19.24306082v1.34","doi-asserted-by":"crossref","unstructured":"Ghobrial IM , Gormley N , Kumar SK , et al: Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma. Blood Cancer Discovery:OF1\u2013OF7, 2024","DOI":"10.1158\/2643-3230.BCD-24-0022"},{"key":"2024042307500992000_2024.04.19.24306082v1.35","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/bloodadvances.2021006762","article-title":"Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma","volume":"6","year":"2022","journal-title":"Blood Adv"},{"key":"2024042307500992000_2024.04.19.24306082v1.36","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018016998"},{"key":"2024042307500992000_2024.04.19.24306082v1.37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114426"},{"key":"2024042307500992000_2024.04.19.24306082v1.38","doi-asserted-by":"crossref","unstructured":"El-Khoury H , Lee DJ , Alberge JB , et al: Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematol, 2022","DOI":"10.1016\/S2352-3026(22)00069-2"},{"key":"2024042307500992000_2024.04.19.24306082v1.39","unstructured":"Sakrikar D , Marrot N , North S , et al: Multi-Site Verification of the Automated EXENT(R) MALDI-TOF-MS System and Immunoglobulin Isotypes Assay for the Identification and Quantification of Monoclonal Immunoglobulins, 2021 AACC Annual Scientific Meeting, 2021"},{"key":"2024042307500992000_2024.04.19.24306082v1.40","doi-asserted-by":"publisher","DOI":"10.2307\/2529310"},{"key":"2024042307500992000_2024.04.19.24306082v1.41","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1158\/2159-8290.CD-22-0482","article-title":"MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology","volume":"13","year":"2023","journal-title":"Cancer Discov"},{"key":"2024042307500992000_2024.04.19.24306082v1.42","unstructured":"Li H : Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv preprint arXiv:1303.3997, 2013"},{"key":"2024042307500992000_2024.04.19.24306082v1.43","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-018-0051-x"},{"key":"2024042307500992000_2024.04.19.24306082v1.44","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2203"},{"key":"2024042307500992000_2024.04.19.24306082v1.45","doi-asserted-by":"crossref","unstructured":"Morton LM , Karyadi DM , Stewart C , et al: Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident. Science 372, 2021","DOI":"10.1126\/science.abg2538"},{"key":"2024042307500992000_2024.04.19.24306082v1.46","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14049"},{"key":"2024042307500992000_2024.04.19.24306082v1.47","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cels.2018.11.005","article-title":"Scrublet: Computational Identification of Cell Doublets in Single-Cell Transcriptomic Data","volume":"8","year":"2019","journal-title":"Cell Syst"},{"key":"2024042307500992000_2024.04.19.24306082v1.48","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btz698"},{"key":"2024042307500992000_2024.04.19.24306082v1.49","doi-asserted-by":"crossref","first-page":"979","DOI":"10.12688\/f1000research.73600.1","article-title":"Doublet identification in single-cell sequencing data using scDblFinder","volume":"10","year":"2021","journal-title":"F1000Res"},{"key":"2024042307500992000_2024.04.19.24306082v1.50","doi-asserted-by":"crossref","first-page":"14049","DOI":"10.1038\/ncomms14049","article-title":"Massively parallel digital transcriptional profiling of single cells","volume":"8","year":"2017","journal-title":"Nature Communications"},{"key":"2024042307500992000_2024.04.19.24306082v1.51","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.04.19.24306082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:58:49Z","timestamp":1768507129000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.04.19.24306082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":51,"URL":"https:\/\/doi.org\/10.1101\/2024.04.19.24306082","relation":{},"subject":[],"published":{"date-parts":[[2024,4,19]]},"subtype":"preprint"}}